Efficacy of coenzyme Q10 in patients with cardiac failure: a meta-analysis of clinical trials

Table 1 Characteristics of the included studies

	Sample size(T/C)	Mean Age(T/C)	Intervation		NYHA	LVEF (%)
			T	C
Alehagen 2015	221/222	59 ± 9	Coenzyme Q10 100 mg, tid	Placebo	II-III	37 ± 7
Belardinelli 2006	23/23	61 ± 10	Coenzyme Q10 100 mg, qd	Placebo	II-IV	22 ± 10
Hofman-Bang 1995	79/79	62 ± 7/61 ± 9	Coenzyme Q10 50 mg, tid	Placebo	II-III	<40
Keogh 2003	19/20	67	Coenzyme Q10 200 mg, qd	Placebo	III-IV	<40
Khatta 2000	28/27	66/67	Coenzyme Q10 50 mg, tid	Placebo	III-IV	NR
Kocharian 2009	17/21	49.8 ± 6.7	Coenzyme Q10 50 mg, tid	Placebo	II-IV	29 ± 11
Morsico 1993	319/322	62 ± 12/62 ± 11	Coenzyme Q10 100 mg, tid	Placebo	II-IV	31 ± 10
Morsico 1994	6/6	60/54	Coenzyme Q10 100 mg, bid	Placebo	II-III	26 ± 6/31 ± 5
Mortensen 2014	202/218	52 ± 9	Coenzyme Q10 33.3 mg, tid	Placebo	I-III	38 ± 16/40 ± 11
Munkholm 1999	11/11	51 ± 13/55 ± 15	Coenzyme Q10 100 mg, bid + atorvastatin	Placebo	II-IV	19 ± 10/26 ± 10
Permanetter 1992	15/10	63 ± 7/62 ± 6	Coenzyme Q10 30 mg, qd	Placebo	II-IV	38 ± 3/36 ± 4
Pourmoghaddas 2014	32/30	55 ± 11	Coenzyme Q10 33 mg, tid	Placebo	NR	26 ± 6
Watson 1999	30/30	78	Coenzyme Q10 100 mg, bid	Placebo	I-III	NR
Zhao 2015	62/66	6 ± 5/7 ± 5	Coenzyme Q10 2 mg/kg/day in 2 or 3 divided doses	Placebo	NR	29 ± 10/33 ± 10

ISSN: 1471-2261